Mohareb A. M., Larmarange Joseph, Kim A. Y., Coffie P. A., Kouame M. G., Boyd A., Freedberg K. A., Hyle E. P. (2022). Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. Lancet HIV, 9 (8), E585-E594. ISSN 2352-3018.
Titre du document
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B
Mohareb A. M., Larmarange Joseph, Kim A. Y., Coffie P. A., Kouame M. G., Boyd A., Freedberg K. A., Hyle E. P.
Source
Lancet HIV, 2022,
9 (8), E585-E594 ISSN 2352-3018
Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation.
